Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat real-world cohort study in Chinese patients with HFrEF
ChiCTR2300076162Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vericiguat in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Left ventricular end-diastolic volume. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2300076162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076162.